Synthimed Labs Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from EDQM and WHO-GMP.
One of their notable products is QUETIAPINE FUMARATE USP, with a corresponding US DMF Number 33190.
Remarkably, this DMF maintains an Active status since its submission on February 06, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 10, 2019, and payment made on March 22, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II